Contract drug maker Catalent Inc. is expanding its US production of Moderna Inc.’s Covid-19 vaccine, a development that could ensure the US has ample supply as vaccines ramp up.
Catalent has reached an agreement with Moderna that will increase the speed of vaccine production at the contracted manufacturer’s plant in Bloomington, Indiana, this month to about 400 vials per minute, according to people familiar with the matter.
Catalent will change injection manufacturing to one faster production line from two slower ones. The new doses will be ready to ship starting next month, the people said, and the upgraded plant will be able to fill an additional 80 million vials a year.
The expansion will help Moderna reach its goal of supplying an additional 100 million doses to the US by the end of May and another 100 million doses by the end of July.
Production in the US of several licensed vaccines has accelerated in recent weeks as manufacturers have expanded production lines and taken other steps to increase production.